Abstract:Background: A comprehensive real-world analysis of residual risk factors for recurrent major adverse cardiovascular events (MACE) following hospital admission for acute coronary syndrome (ACS) is lacking. The objectives of this study were: 1) to describe population trends for outcomes, risk factors, and medication prescribing patterns post-ACS and 2) to identify factors associated with recurrent MACE. Methods: A retrospective cohort study of 4,884 post-ACS patients admitted at a large integrated healthcare system between 2015-2021 was performed to investigate the relationship between recurrent MACE (ACS, cerebrovascular events, all-cause mortality, and unplanned revascularization), modifiable risk factor trends, and medical therapy prescribing patterns. Patients were separated into 2 cohorts based upon whether they experienced recurrent MACE following the initial hospitalization. Data were obtained via programmatic extraction from the electronic health record. Descriptive statistics were performed. Generalized linear models were used to assess risk factor trends and pairwise comparisons were performed between time points. Results: Median length of follow-up after ACS was 31.2 months. Recurrent MACE occurred in 28% of patients. Despite 95.9% of all patients receiving prescriptions for high-intensity statins, >40% did not achieve LDL-C goal of <70 mg/dL, and only 11.6% and 2.6% of all patients were prescribed ezetimibe or proprotein convertase subtilisin kexin type 9 inhibiting monoclonal antibodies, respectively. Although >30.0% of patients had triglycerides ≥150 mg/dL at all time points, ≤6% were prescribed any non-statin triglyceride lowering therapy and 0.6% were prescribed icosapent ethyl. Persistent hypertriglyceridemia (≥150 mg/dL) was associated with recurrent MACE at 6-, 12-, and 24-months post-ACS (p<0.05), and the relative risk ranged between 1.20-1.35 at those timepoints. Conclusions: This study demonstrates the need for more comprehensive post-ACS care to address residual cardiometabolic risk factors and suboptimal prescribing patterns for indicated therapies. Targeted strategies are needed to address hypertriglyceridemia for cardiovascular risk reduction.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to comprehensively analyze the residual risk factors and the trend of recurrent major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) after discharge, as well as the changes in medical prescription patterns. Specifically, the study aims to: 1. **Describe population trends**: including the trends of outcomes, risk factors, and drug prescription patterns after ACS. 2. **Identify factors associated with recurrent MACE**: By analyzing these factors, understand which factors may cause ACS patients to experience MACE again after discharge. ### Research Background Acute coronary syndrome (ACS) is one of the most serious consequences of coronary heart disease (CHD), resulting in more than 1 million hospitalizations and 2.4 million deaths in the United States each year. Although guideline - directed medical therapy (GDMT) and lifestyle changes are key to reducing recurrent MACE after ACS, many patients still fail to reach the ideal level of risk control, and the implementation of evidence - supported guidelines is often not ideal. ### Research Objectives 1. **Describe population trends**: Analyze the trends of outcomes, risk factors, and drug prescription patterns in patients after ACS. 2. **Identify factors associated with recurrent MACE**: Determine which factors are significantly associated with recurrent MACE after ACS. ### Research Methods - **Study design**: A retrospective cohort study that included 4,884 patients who were hospitalized for ACS in the Geisinger healthcare system between 2015 and 2021 and had at least 6 months of follow - up data. - **Grouping**: Patients were divided into four cohorts according to whether they experienced recurrent MACE after the initial hospitalization. - **Primary outcome**: 4 - point MACE (recurrent ACS, unplanned coronary revascularization, cerebrovascular events, and all - cause death). - **Secondary outcome**: 3 - point MACE (recurrent ACS, cerebrovascular events, and all - cause death). ### Main Findings - **Incidence of recurrent MACE**: 28% of patients experienced recurrent MACE after a median follow - up of 31.2 months. - **Poor lipid control**: Although 95.9% of patients received high - dose statin therapy, more than 40% of patients failed to reach the LDL - C target (<70 mg/dL), and only 11.6% and 2.6% of patients received ezetimibe and PCSK9 inhibitor monoclonal antibody therapy, respectively. - **Hypertriglyceridemia**: Persistent hypertriglyceridemia (≥150 mg/dL) was significantly associated with recurrent MACE, with relative risks of 1.20 - 1.35 at 6, 12, and 24 months, respectively. - **Poor glycemic control**: The proportion of patients with HbA1c >7.0% at baseline was significantly higher in the recurrent MACE cohort, and this trend continued at subsequent time points. ### Conclusion This study emphasizes the need for more comprehensive post - ACS care to address residual cardiometabolic risk factors and suboptimal drug prescription patterns. In particular, strategies targeting hypertriglyceridemia are crucial for reducing cardiovascular risk.

Analysis of Residual Risk and Recurrent Event Trends Following Acute Coronary Syndrome: A Cohort Study

Predictors of Recurrent Angina in Patients with No Need for Secondary Revascularization.

Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design

Recurrent cardiovascular and limb events in 294,428 patients with coronary or peripheral artery disease or ischemic stroke on antiplatelet monotherapy: The RESRISK cohort study

Risk of recurrent ischaemic events in ACS patients with baseline LDL-C below guideline-recommended thresholds: insights from the prospective SPUM-ACS study

Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients

Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III

P3609Temporal trends of the management and outcomes of patients after myocardial infarction according to the risk for recurrent cardiovascular events

Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review

Impact of the completeness of revascularization and high bleeding risk status in acute coronary syndrome patients with multi-vessel disease: A retrospective analysis

Long-term Follow-Up of Antithrombotic Management Patterns in Patients with Acute Coronary Syndrome in China

Risk factors for adverse outcomes of patients with acute coronary syndrome: single-centre experience with long-term follow-up of treated patients

Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population

Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study

Novel Targets and Strategies Addressing Residual Cardiovascular Risk in Post-acute Coronary Syndromes Patients

Assessing Prognosis of Acute Coronary Syndrome in Recent Clinical Trials: A Systematic Review

Clinical characteristics and predictors of recurrence from the Australia-New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) registry

Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J

Clinical characteristics and outcomes of patients with acute coronary syndrome without standard metabolic cardiovascular risk factors

Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI